Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas

BMJ Open Respir Res. 2020 Jun;7(1):e000505. doi: 10.1136/bmjresp-2019-000505.

Abstract

Background Despite improved screening techniques, diagnosis of lung cancer is often late and its prognosis is poor. In the present study, in vitro chemosensitivity of solid tumours and pleural effusions of lung adenocarcinomas were analysed and compared with clinical drug response.Methods Tumour cells were isolated from resected solid tumours or pleural effusions, and cryopreserved. Three-dimensional (3D) tissue aggregate cultures were set up when the oncoteam reached therapy decision for individual patients. The aggregates were then treated with the selected drug or drug combination and in vitro chemosensitivity was tested individually measuring ATP levels. The clinical response to therapy was assessed by standard clinical evaluation over an 18 months period.Results Based on the data, the in vitro chemosensitivity test results correlate well with clinical treatment response.Conclusions Such tests if implemented into the clinical decision making process might allow the selection of an even more individualised chemotherapy protocol which could lead to better therapy response.

Keywords: lung cancer; lung cancer chemotherapy; non-small cell lung cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / complications
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Drug Screening Assays, Antitumor / methods*
  • Feasibility Studies
  • Humans
  • Lung Neoplasms / complications
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Pleural Effusion, Malignant / complications
  • Pleural Effusion, Malignant / drug therapy*
  • Pleural Effusion, Malignant / pathology
  • Prognosis
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents